Citius Pharmaceuticals Reaches Nasdaq Compliance Milestone, Analysts Weigh In

Citius Pharmaceuticals regained Nasdaq compliance after maintaining a closing bid price of $1.00 or greater for 10 consecutive trading days. The company's stock is listed on the Nasdaq Stock Market, and Citius Pharma aims to deliver critical care products and create long-term value for shareholders. The latest analyst rating on CTXR stock is a Buy with a $100.00 price target.

Citius Pharmaceuticals, Inc. (CTXR) has successfully regained compliance with Nasdaq's minimum bid price requirement, a significant milestone for the biopharmaceutical company. The company's stock maintained a closing bid price of $1.00 or higher for 10 consecutive trading days, from June 20, 2025, to July 3, 2025 [2, 3]. This achievement has ensured that CTXR will continue to be listed and traded on the Nasdaq Stock Market, avoiding a potential delisting hearing [2, 3].

Citius Pharmaceuticals, founded in 2007 and headquartered in Cranford, New Jersey, is dedicated to the development and commercialization of first-in-class critical care products. The company's FDA-approved product, LYMPHIR, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. Additionally, Citius Pharma's late-stage pipeline includes Mino-Lok, an antibiotic lock solution for catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids [1].

The Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023, with Mino-Lok meeting its primary and secondary endpoints [1]. Citius Pharmaceuticals is actively engaged with the FDA to determine the next steps for these programs.

The latest analyst rating on CTXR stock is a Buy with a $100.00 price target, reflecting investor confidence in the company's pipeline and strategic focus on critical care products [1].

References:
[1] https://finance.yahoo.com/quote/CTXR/
[2] https://www.gurufocus.com/news/2963406/citius-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-requirement-ctxr-stock-news
[3] https://www.prnewswire.com/news-releases/citius-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-requirement-302499666.html